Literature DB >> 6883340

Variable 5-methylcytosine levels in human tumor cell lines and fresh pediatric tumor explants.

E Flatau, E Bogenmann, P A Jones.   

Abstract

DNA methylation was measured in human tumor cell lines and freshly explanted pediatric tumors by [3H]uridine labeling followed by DNA hydrolysis and high-performance liquid chromatography. The percentage of cytosine residues modified to 5-methylcytosine in 4 cell lines derived from pediatric tumors was increased or similar to the levels of 3.45% found in two strains of diploid human fibroblasts. However, a fibrosarcoma line derived from an adult (HT1080) contained decreased levels of 5-methylcytosine. Four low-passage retinoblastomas had uniform 5-methylcytosine levels of approximately 3.9%, whereas the levels of the modified base in two freshly explanted rhabdomyosarcomas, one Wilms' tumor, and one medulloblastoma were 3.39, 3.56, and 3.45%, respectively. Two neuroblastomas had substantially lower levels (2.63 to 2.83%) of 5-methylcytosine in their DNAs compared to the retinoblastomas, which are also derived from neural tissue. The results show that while tumors of the same histological type had similar 5-methylcytosine values, discrepancies existed between values obtained for fresh tumors and their corresponding cell lines. Tumor cell lines may therefore be inadequate models for studies on the relationship between DNA methylation and cancer. The results also indicate that generalized statements on DNA methylation levels in pediatric tumors cannot be made, although substantial variations may occur between different tumors types.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6883340

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Studies on the mechanism of the synergistic interaction between 2'-deoxy-5-azacytidine and cisplatin.

Authors:  J L Abbruzzese; P Frost
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Colorectal cancer: a model for epigenetic tumorigenesis.

Authors:  J J L Wong; N J Hawkins; R L Ward
Journal:  Gut       Date:  2006-07-13       Impact factor: 23.059

Review 3.  DNA hypomethylation in the origin and pathogenesis of human diseases.

Authors:  Igor P Pogribny; Frederick A Beland
Journal:  Cell Mol Life Sci       Date:  2009-03-27       Impact factor: 9.261

4.  Lack of correlation between DNA-methylating activity and appearance of the immunogenic phenotype in clones of a murine lymphoma treated with mutagens.

Authors:  P Fuschiotti; M C Fioretti; L Romani; P Puccetti
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative.

Authors:  M Allegrucci; P Fuschiotti; P Puccetti; L Romani; M C Fioretti
Journal:  Clin Exp Metastasis       Date:  1989 May-Jun       Impact factor: 5.150

6.  Cytosine methylation does not affect binding of transcription factor Sp1.

Authors:  M A Harrington; P A Jones; M Imagawa; M Karin
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

7.  DNA methylation in 5-aza-2'-deoxycytidine-resistant variants of C3H 10T1/2 C18 cells.

Authors:  E Flatau; F A Gonzales; L A Michalowsky; P A Jones
Journal:  Mol Cell Biol       Date:  1984-10       Impact factor: 4.272

8.  Induction of a step in carcinogenesis that is normally associated with mutagenesis by nonmutagenic concentrations of 5-azacytidine.

Authors:  N Bouck; D Kokkinakis; J Ostrowsky
Journal:  Mol Cell Biol       Date:  1984-07       Impact factor: 4.272

9.  DNA methylation profiles in the human genes for tumor necrosis factors alpha and beta in subpopulations of leukocytes and in leukemias.

Authors:  S Kochanek; A Radbruch; H Tesch; D Renz; W Doerfler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-01       Impact factor: 11.205

10.  Ubiquitous and tenacious methylation of the CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutational hot spot in human cancer.

Authors:  A N Magewu; P A Jones
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.